I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 MWnjfZRwfG:6aXPpeJkh[XO|YYm= M4HYSJ4yODBizszN M1zyNGROW09? MVPJR|UxRTJ4IH7N NE\HSoozOTl4NEO0NC=>
RS4;11 NEGyNGhkgXSxdH;4bYNqfHliYYPzZZk> NXHLdXIxhjFyMDFOwG0> NF\wXoRFVVOR M2HV[WlEPTB;MUmyJI5O NV\tVI5vOjF7NkSzOFA>
MOLM13 MnLzZ5l1d3SxeHnjbZR6KGG|c3H5 M1y3UZ4yODBizszN M4PpSmROW09? MXvJR|UxRTF{MDDuUS=> NVviWYtyOjF7NkSzOFA>
NOMO1 MXfjfZRwfG:6aXPpeJkh[XO|YYm= NU\D[HlShjFyMDFOwG0> NX3sdWdRTE2VTx?= MYrJR|UxRTF3IH7N M4nIfVIyQTZ2M{Sw
HEL Ml24Z5l1d3SxeHnjbZR6KGG|c3H5 NVy4UFRIhjFyMDFOwG0> MV;EUXNQ Mn[yTWM2OD1zIN88US=> NYnlZYhWOjF7NkSzOFA>
K562 NFLpbINkgXSxdH;4bYNqfHliYYPzZZk> NXPnfHJ2hjFyMDFOwG0> NYDnfJY6TE2VTx?= MoP2TWM2OD5zMECg{txO MXOyNVk3PDN2MB?=
MEG01 MVHjfZRwfG:6aXPpeJkh[XO|YYm= MlvZglExOCEQvF2= NVn3VJplTE2VTx?= MnLLTWM2OD1{NTFOwG0> NG\KPZAzOTl4NEO0NC=>
HL60 NHnmS3BkgXSxdH;4bYNqfHliYYPzZZk> NHL0Uph,OTByIN88US=> NHzOeIZFVVOR MV\JR|UxRTh7MDDuUS=> MnLYNlE6PjR|NEC=
MV4;11 NF\OcVdCeG:ydH;zbZMh[XO|YYm= MoOzglExOCEQvF2= NEPGUFdFVVOR MUnpcoR2[2W|IHHwc5B1d3Orcx?= NGPlOVUzOTl4NEO0NC=>
MOLM13 MVnBdI9xfG:|aYOgZZN{[Xl? MWT+NVAxKM7:TR?= M{S5OGROW09? NGnHTnZqdmS3Y3XzJIFxd3C2b4Ppdy=> MWeyNVk3PDN2MB?=
MV4;11 Mmn6SpVv[3Srb36gZZN{[Xl? M4j1SWROW09? M1zQRYRm[3KnYYPld{B1cGVicnXjdpVqfG2nboSgc4YhSlKGMz:0JIFv\CCrbYDhbZJm\CC{ZXPyeYl1dWWwdDDv[kBETEt7IHHu[EBRSUZzIITvJJRp\SC2cnHud4NzcXC2aX;uZYwhe3SjcoSgd4l1\Q>? MXSyNVk3PDN2MB?=
PBMC M4L3ZWZ2dmO2aX;uJIF{e2G7 NYLTUXM5TE2VTx?= Mk\ibY5pcWKrdIOgTWwuPiC5aYToJJBKSzVyIH;mJFYvPw>? MUeyNlQ{PzFzNR?=
A2 NG\2OGRHfW6ldHnvckBie3OjeR?= NXTrb2pQhjFyIN88US=> MYfEUXNQ NWizc3ZqemWjY4TpeoF1\XNibHH0[Y51KEiLVj2x NYH0OGRjOjN{NUWyNVg>
A72 NUS4OnF1TnWwY4Tpc44h[XO|YYm= NF[0b41,OTBizszN MUTEUXNQ M4fjPZJm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= NUj4RnczOjN{NUWyNVg>
BC1 MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGn6NFN,OSEQvF2= NH3KbWtFVVOR NYS3V3RKUUN3ME2yNlAhdk1? NWHEc2FvOjN5OUK0OFg>
BC3 MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2fvZZ4yKM7:TR?= NFv5N|ZFVVOR MWLJR|UxRTR4MDDuUS=> NHrOWGQzOzd7MkS0PC=>
BCBL1 Mk\nS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Moi2glEh|ryP MV\EUXNQ NHfaTJJKSzVyPUOzNEBvVQ>? NVjZ[Ys6OjN5OUK0OFg>
BJAB MoHvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnX0glEh|ryP M364RmROW09? NWW2O2tGUUN3ME25O|Ahdk1? MXWyN|c6OjR2OB?=
Namalwa MkfTS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVP4NJg4hjFizszN Mn3nSG1UVw>? NXTySFJFUUN3ME25O|Ahdk1? MVWyN|c6OjR2OB?=
Jurkat NGKwOVRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGS3dZR,OSEQvF2= M3jnT2ROW09? MmT2TWM2OD1zMkKwJI5O NHmwXFYzOzd7MkS0PC=>
MM1S NIPzUZRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{LGNp4yKM7:TR?= MVfEUXNQ MXLJR|UxRTd4MDDuUS=> MUWyN|c6OjR2OB?=
U266 NEjLNYdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXvGOplyhjFizszN MVnEUXNQ MnjWTWM2OD17NUCgcm0> MorVNlM4QTJ2NEi=
UM-PEL-1 NWH4e2pNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NIrjTpl,OSEQvF2= NIHWeZNFVVOR NHS1U21KSzVyPUKxNEBvVQ>? MXSyN|c6OjR2OB?=
UM-PEL-3 NYS1T3pHT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M{HhS54yKM7:TR?= NUTKbodLTE2VTx?= NGPYZotKSzVyPUG4NEBvVQ>? NYDze2YxOjN5OUK0OFg>
BC1 NYT5O5dXTnWwY4Tpc44h[XO|YYm= NVXmcYQ6PTByIH7N M1PNW2ROW09? NWPMWYdRcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> MoP6NlM4QTJ2NEi=
BC3 M3\aUGZ2dmO2aX;uJIF{e2G7 M1O3e|UxOCCwTR?= MnPVSG1UVw>? NYDyPYx2cW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> M2jWRlI{Pzl{NES4
BC1 NH7RTZFHfW6ldHnvckBie3OjeR?= NH64W5I5ODBibl2= M1zuc2ROW09? NWrj[IJRemWmdXPld{BkNU27YzDwdo91\WmwIHzleoVtew>? MXWyN|c6OjR2OB?=
BC3 NXTQ[5JwTnWwY4Tpc44h[XO|YYm= MV[4NFAhdk1? M{D5ZmROW09? M2rhdpJm\HWlZYOgZ{1OgWNicILveIVqdiCuZY\lcJM> Ml;mNlM4QTJ2NEi=
H929 M4jEVWZ2dmO2aX;uJIF{e2G7 NFXUOXF,OSEQvF2= MnWxSG1UVw>? NVfXdnYxcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MVmyOFM{PTR7OR?=
KMS12PE M3\UWmZ2dmO2aX;uJIF{e2G7 M{HUZ54yKM7:TR?= MkXHSG1UVw>? NIHXdllqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NHK1bYYzPDN|NUS5PS=>
KMS12BM MnO3SpVv[3Srb36gZZN{[Xl? M36yTJ4yKM7:TR?= NV;P[m9LTE2VTx?= NWjTWG1{cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MUeyOFM{PTR7OR?=
KMS18 NGLCfHhHfW6ldHnvckBie3OjeR?= NFzQUoh,OSEQvF2= NWHrflROTE2VTx?= NWThVYI{cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MkPrNlQ{OzV2OUm=
KMS11 M2[3WWZ2dmO2aX;uJIF{e2G7 NFPvTYd,OSEQvF2= NYrCWIxJTE2VTx?= MoKzbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NFPsS4szPDN|NUS5PS=>
RPMI8226 NILiTIRHfW6ldHnvckBie3OjeR?= NFi3R5B,OSEQvF2= NVTYTYtkTE2VTx?= NYm3[5EycW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MmDPNlQ{OzV2OUm=
H929 MljHRZBweHSxc3nzJIF{e2G7 NF3FSYV,OSEQvF2= NG\0ToxFVVOR NGrnTZRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlTwNlQ{OzV2OUm=
KMS12PE M2naU2Fxd3C2b4Ppd{Bie3OjeR?= NGC0Wot,OSEQvF2= MoKzSG1UVw>? NVPwcnN3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXOyOFM{PTR7OR?=
KMS12BM NFjYeI1CeG:ydH;zbZMh[XO|YYm= NYDqWVVzhjFizszN M{H4cmROW09? Mn7UbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYGyOFM{PTR7OR?=
KMS18 NHXtUWlCeG:ydH;zbZMh[XO|YYm= NGfrXJh,OSEQvF2= NISydllFVVOR NFLROnJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NIDtSlkzPDN|NUS5PS=>
KMS11 Mm\5RZBweHSxc3nzJIF{e2G7 MofEglEh|ryP NUnVdplZTE2VTx?= M1rnOYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1;MSlI1OzN3NEm5
RPMI8226 NITYUZVCeG:ydH;zbZMh[XO|YYm= M2DLep4yKM7:TR?= NHXYTGZFVVOR M2n5UIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MYeyOFM{PTR7OR?=
U87MG NGPLd29HfW6ldHnvckBie3OjeR?= Ml\VglExKM7:TR?= NGrM[JNFVVOR NYPDc495emWmdXPld{BWQDePRzDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEGuNFUh|ryP NGm4cnozPDR7NkO4NS=>
A172 MV7GeY5kfGmxbjDhd5NigQ>? MWP+NVAh|ryP NYTnRnoyTE2VTx?= M4m0XZJm\HWlZYOgZ4VtdHWuYYKgRXRRKHerdHigTWM2OCCxZjCxMlI5KM7:TR?= NILDZoEzPDR7NkO4NS=>
SW1783 MV\GeY5kfGmxbjDhd5NigQ>? NGrzd5d,OTBizszN MVfEUXNQ NGXNUJlz\WS3Y3XzJINmdGy3bHHyJGFVWCC5aYToJGlEPTBib3[gNk43QCEQvF2= NWHqPZkyOjR2OU[zPFE>
U87MG MVTGeY5kfGmxbjDhd5NigQ>? NFf1OG9,OTBizszN NGTlSHNFVVOR MknVbY5kemWjc3XzJJBzd3CxcoTpc44hd2ZiY3XscJMhcW5idHjlJGcyN1NidILhcpNqfGmxbh?= NV7HRodXOjR2OU[zPFE>
RAW267.4 Mk\SSpVv[3Srb36gZZN{[Xl? MoeyNUDPxE1? M1;KTWROW09? MVHy[YR2[2W|IFnMMVYheHKxZIXjeIlwdiCrbnT1Z4VlKGK7IFzQVy=> NVLJNZFLOjR6NUmwNFg>
RAW267.4 MULGeY5kfGmxbjDhd5NigQ>? M{LWblEh|ryP NG[zR5VFVVOR M2e0VZJm\HWlZYOgeIhmKGG|c3;jbYF1cW:wIHLleJdm\W5iQmLEOEBidmRiYXPleJlt[XSnZDDwOlU> M3fOW|I1QDV7MEC4
Me007 M2LCdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3LDVp4yODBizszN MVzEUXNQ MYTpcohq[mm2czD0bIUh\3Kxd4To MmK2NlQ6ODZzM{e=
SK-Mel-28 MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3rJU54yODBizszN MXHEUXNQ NGXld2NqdmirYnn0d{B1cGViZ4Lve5Rp MoHMNlQ6ODZzM{e=
Mel-RMU MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFLIdoF,OTByIN88US=> MWTEUXNQ NH3Ue|ZqdmirYnn0d{B1cGViZ4Lve5Rp MnnxNlQ6ODZzM{e=
Mel-JD NEPGUWFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3Hudp4yODBizszN NWjHZpJXTE2VTx?= MojYbY5pcWKrdIOgeIhmKGe{b4f0bC=> NV3WO2NpOjR7ME[xN|c>
Mel-RM MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NX;rNppmhjFyMDFOwG0> MYnEUXNQ NGP0S4dqdmirYnn0d{B1cGViZ4Lve5Rp M3rQWVI1QTB4MUO3
Me007 MXLBdI9xfG:|aYOgZZN{[Xl? MYr+NVAxKM7:TR?= Mne5SG1UVw>? Mm\WbY5lfWOnczDhdI9xfG:|aYO= MX:yOFkxPjF|Nx?=
SK-Mel-28 MVTBdI9xfG:|aYOgZZN{[Xl? NI[yNYd,OTByIN88US=> NYTLb3pPTE2VTx?= NWHQXZZScW6mdXPld{BieG:ydH;zbZM> M4Hs[|I1QTB4MUO3
Mel-RMU MmLKRZBweHSxc3nzJIF{e2G7 NIrLW4h,OTByIN88US=> NUjEcmdbTE2VTx?= MXvpcoR2[2W|IHHwc5B1d3Orcx?= M13XR|I1QTB4MUO3
Mel-JD NFuyNIlCeG:ydH;zbZMh[XO|YYm= NWPNclJFhjFyMDFOwG0> M1\PeWROW09? MWrpcoR2[2W|IHHwc5B1d3Orcx?= MnroNlQ6ODZzM{e=
Mel-RM MmDvRZBweHSxc3nzJIF{e2G7 NGf0Xol,OTByIN88US=> MkfKSG1UVw>? Mlr0bY5lfWOnczDhdI9xfG:|aYO= M3vtflI1QTB4MUO3
Me007 NFK2dnZHfW6ldHnvckBie3OjeR?= MYmxNEDPxE1? NXvWXmJRTE2VTx?= NIXiPHBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? NFrx[HkzPDlyNkGzOy=>
SK-Mel-28 MnrHSpVv[3Srb36gZZN{[Xl? MoPwNVAh|ryP M1TaUmROW09? M4jGRolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? MYKyOFkxPjF|Nx?=
Mel-RMU NFG5cVZHfW6ldHnvckBie3OjeR?= NI\afm0yOCEQvF2= Mn\FSG1UVw>? M2rjSolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? MoTXNlQ6ODZzM{e=
Mel-JD MmXISpVv[3Srb36gZZN{[Xl? NGPLRVMyOCEQvF2= M2DvNmROW09? MXHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> NVTIPZJtOjR7ME[xN|c>
Mel-RM NU[1RVExTnWwY4Tpc44h[XO|YYm= Mn;QNVAh|ryP MWjEUXNQ MmjSbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NY\5Z|lqOjR7ME[xN|c>
Me007 NWPvNpRDTnWwY4Tpc44h[XO|YYm= NGrKTIoyOCEQvF2= MWHEUXNQ MVj1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| M4LsZ|I1QTB4MUO3
SK-Mel-28 M374OGZ2dmO2aX;uJIF{e2G7 NHXhO28yOCEQvF2= NG\tWnBFVVOR NFrwSop2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz MnfoNlQ6ODZzM{e=
Mel-RMU M1TSbWZ2dmO2aX;uJIF{e2G7 MkG2NVAh|ryP MW\EUXNQ NV3ic2twfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> MnzSNlQ6ODZzM{e=
Mel-JD MlnISpVv[3Srb36gZZN{[Xl? NE\qPZQyOCEQvF2= NGLZXmRFVVOR MnfKeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= NX\zcJQ6OjR7ME[xN|c>
Mel-RM NYHnVVFxTnWwY4Tpc44h[XO|YYm= M2\YSlExKM7:TR?= MoO0SG1UVw>? MVP1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| NIXLWoQzPDlyNkGzOy=>

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID